Analytical Data
-
Gene name
HLA-A*02:01&B2M&PRAME(SLLQHLIGL) Monomer
- Application
-
Alternative Names
Opa-interacting protein 4 ;OIP-4Preferentially expressed antigen of melanoma
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P78395
-
Expression Region
1-509aa
-
Molecular Weight
59.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is a highly prevalent human leukocyte antigen (HLA) class I molecule that plays a crucial role in the immune response by presenting endogenous peptides to CD8+ T cells. The peptide presented by HLA-A*02:01 can significantly impact T cell recognition and subsequent immune responses, making it a key target in cancer immunotherapy and vaccine development. β2-microglobulin (B2M) is an essential component of the HLA class I complex, stabilizing its structure and facilitating efficient antigen presentation. The PRAME (Preferentially Expressed Antigen in Melanoma) antigen, specifically the peptide SLLQHLIGL, has garnered attention due to its overexpression in various malignancies, including melanoma, rendering it a compelling target for tumor-specific T cell responses. The study of HLA-A*02:01 in conjunction with B2M and the PRAME peptide SLLQHLIGL involves the generation of a recombinant monomeric protein, which enables researchers to investigate the molecular interactions and stability of the HLA-peptide complex. This can further our understanding of the immune recognition process and contribute to the design of targeted immunotherapies. Overall, the combination of HLA-A*02:01, B2M, and PRAME peptide SLLQHLIGL represents a significant area of study with potential implications for enhancing cancer treatment strategies through targeted immune activation.
